About

We're a company that cares about quality - of our products, service, and most importantly, the quality of our patients' well being.

Ease of Use. Advanced medical technology with accessibility to all.

The Regen system is designed to limit pre-clinical and outpatient care, and streamline the process by requiring less than 30 minutes of outpatient time, per patient.

Efficacy. Highly tolerable proprietary technology.

Conclusive evidence demonstrates that Regen's products are safe and improves quality of life for patients, while regenerating cartilage and/or bone.

Reduce Costs. Benefiting patients, physicians, and healthcare payor systems.

Regen's ease of outpatient interactivity minimizes recovery timeframe at significantly lower cost to patient and payer and minimal cost to the clinical provider.

Mission. To develop and market innovative products for improving the medical and economic outcomes of osteoarthritis and bone related medical conditions.

Values. Regen is dedicated to the betterment of ourselves, the industry, and others. To achieve this, we diligently follow these principles.

Find A Better Way

We foster a culture of innovation and continuous improvement to find the best solutions.

Do The Right Thing

We are guided by a solid moral compass and hold ourselves to a high level of ethical standards.

Data Driven

We make strategic decisions based on data analysis to better serve our partners.

Management Team. A seasoned founding team, skilled in management, technology, sales, and marketing.

Dr. Anil Vaidya is a multi-organ transplant surgeon with a varied clinical, translational and academic portfolio. He is credited with world-first ground breaking multi-organ transplant for Pseudo-Myxoma Peritonei and having done the first composite tissue allograft (CTA) transplant in the UK in the form of vascularised abdominal wall transplantation to complement intestinal transplantation. Dr. Anil Vaidya is also the first surgeon in the world to successfully use Stem Cells to treat a patient with intractable bowel dysfunction after intestinal transplantation. He has authored 120 articles in peer-reviewed journals and his rating by Research Gate puts him among the top 3% of the surgeons in the world.

Anil Vaidya MD DNB, ASTS, CCT

CEO
Assoc. Prof. of Colorectal Surgery at Cleveland Clinic, Assoc. Chair of Surgical Research, with a focus on regenerative therapy.

Amy Lightner MD

CMO
Ph.D in Chemistry from the Advanced Studies and Research Center (CINVESTAV IPN) in México City with 10 years experience conducting multidisciplinary research for academic and private sectors.

Brenda Paz, PhD

CSO
Industry professional with expertise in product management, operations, marketing and financial technologies.

Mitch Somach

Head of Business Operations
Highly skilled Legal & Strategy Executive with experience as a strategic business partner and high-level project manager.

Juliana Fitzpatrick

General Counsel & Head of People

Strategic Advisors. Individuals well known in their respective industries willing to share their knowledge and connections.

Brain Connectivity Unit D'Or Institute for Research and Education and Federal University of Rio de Janeiro, Postdoctoral Fellowship award at the National Institutes of Health, cofounding members of the International Research Consortium for the Corpus Callosum and Cerebral Connectivity (IRC5).

Fernanda Tovar-Moll MD, PhD

Dr. Betancourt is a recognized expert in the field of stem cells, cancer, and stem cell-based therapies. She received her B.S. in Biochemistry and Ph.D. in Microbiology.

Aline Betancourt PhD

Strategic Partners. Well established companies that share resources towards growth and mutual success.